Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 19/20 | 0.76 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19894787 | 1.00 | CHRM3 (0.76) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15768664 | 1.00 | CHRM3 (0.76) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15768662 | 1.00 | CHRM3 (0.76) | CHRM3ADRB2CACNA1C | |
| SCHEMBL19894784 | 1.00 | CHRM3 (0.76) | CHRM3ADRB2CACNA1C | |
| SCHEMBL16561284 | 0.95 | CHRM3 (0.78) | CHRM3ADRB2CACNA1C | |
| SCHEMBL19894731 | 0.95 | CHRM3 (0.78) | CHRM3ADRB2CACNA1C | |
| SCHEMBL19894732 | 0.95 | CHRM3 (0.78) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15776276 | 0.95 | CHRM3 (0.78) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15768157 | 0.94 | CHRM3 (0.77) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15768149 | 0.94 | CHRM3 (0.77) | CHRM3ADRB2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928890-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2018-02-28 | — | — | EP | claimed |
| EP-2928890-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2018-02-28 | — | — | EP | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| US-20150139916-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 11/4885ADRB2 1/4885CACNA1C 755/4885 |
| US-20150139916-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 11/4885ADRB2 1/4885CACNA1C 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.